Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Shares Outstanding (Diluted Average): 2018-2024

Historic Shares Outstanding (Diluted Average) for Denali Therapeutics (DNLI) over the last 7 years, with Dec 2024 value amounting to $164.5 million.

  • Denali Therapeutics' Shares Outstanding (Diluted Average) rose 1.75% to $172.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.4 million, marking a year-over-year increase of 1.75%. This contributed to the annual value of $164.5 million for FY2024, which is 19.73% up from last year.
  • Latest data reveals that Denali Therapeutics reported Shares Outstanding (Diluted Average) of $164.5 million as of FY2024, which was up 19.73% from $137.4 million recorded in FY2023.
  • In the past 5 years, Denali Therapeutics' Shares Outstanding (Diluted Average) registered a high of $164.5 million during FY2024, and its lowest value of $112.7 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $137.4 million (2023), whereas its average is $142.5 million.
  • Data for Denali Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY climbed of 19.73% (in 2024) over the last 5 years.
  • Over the past 5 years, Denali Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $112.7 million in 2020, then rose by 7.83% to $121.5 million in 2021, then climbed by 3.30% to $125.5 million in 2022, then rose by 9.43% to $137.4 million in 2023, then rose by 19.73% to $164.5 million in 2024.